- Home
- FINW vs FHTX Comparison
FINW vs FHTX Comparison
Compare FINW & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINW
- FHTX
- Stock Information
- Founded
- FINW 1999
- FHTX 2015
- Country
- FINW United States
- FHTX United States
- Employees
- FINW N/A
- FHTX N/A
- Industry
- FINW Commercial Banks
- FHTX Medicinal Chemicals and Botanical Products
- Sector
- FINW Finance
- FHTX Health Care
- Exchange
- FINW Nasdaq
- FHTX Nasdaq
- Market Cap
- FINW 212.8M
- FHTX 237.4M
- IPO Year
- FINW 2021
- FHTX 2020
- Fundamental
- Price
- FINW $19.25
- FHTX $5.23
- Analyst Decision
- FINW Buy
- FHTX Strong Buy
- Analyst Count
- FINW 4
- FHTX 6
- Target Price
- FINW $20.75
- FHTX $13.17
- AVG Volume (30 Days)
- FINW 37.4K
- FHTX 163.3K
- Earning Date
- FINW 01-30-2025
- FHTX 03-06-2025
- Dividend Yield
- FINW N/A
- FHTX N/A
- EPS Growth
- FINW N/A
- FHTX N/A
- EPS
- FINW 0.93
- FHTX N/A
- Revenue
- FINW $69,824,000.00
- FHTX $25,515,000.00
- Revenue This Year
- FINW N/A
- FHTX N/A
- Revenue Next Year
- FINW $21.91
- FHTX $8.30
- P/E Ratio
- FINW $20.70
- FHTX N/A
- Revenue Growth
- FINW 9.10
- FHTX N/A
- 52 Week Low
- FINW $8.72
- FHTX $3.86
- 52 Week High
- FINW $20.94
- FHTX $10.25
- Technical
- Relative Strength Index (RSI)
- FINW 54.22
- FHTX 52.39
- Support Level
- FINW $19.17
- FHTX $3.89
- Resistance Level
- FINW $20.94
- FHTX $6.27
- Average True Range (ATR)
- FINW 0.82
- FHTX 0.59
- MACD
- FINW -0.02
- FHTX 0.11
- Stochastic Oscillator
- FINW 51.99
- FHTX 48.38
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank also has established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.